



مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

TRASTuzumab + PERTuzumab



* C O M B I N E D - 0 3 - 0 0 1 - B R *



Ministry of Health

Name:

File #:

Ht (cm):

Nationality:

Civil ID:

Wt (Kg):

Gender/Age:

DOB:

BSA (m²):

Indication(s): HER2 +ve breast cancer, Neoadjuvant / Adjuvant / Palliative

Central line: Available NA

Allergies: NKA Yes, specify; _____

Parameters: Baseline ECHO and/or MUGA scan before initiation of Anti-HER2 therapy.

Then, every 3 months during and upon completion of Anti-HER2 therapy.

Then, every 6 months for at least 2 years following completion of Anti-HER2 therapy.

Standard Protocol:

DRUG	DOSE	ADMINISTRATION	DAYS
TRASTuzumab	8 mg/kg (Loading dose)	IV in 250 mL NS over 90 min.	1st dose only
PERTuzumab	840 mg (Loading dose)	IV in 250 mL NS over 60 min.	1st dose only
TRASTuzumab	6 mg/kg (Maintenance)	IV in 250 mL NS over 30 min.	D1
PERTuzumab	420 mg (Maintenance)	IV in 250 mL NS over 60 min.	D1

Neoadjuvant: to be repeated every 3 weeks for 4-6 cycles.
 Adjuvant: to be repeated every 3 weeks for 1 year.
 Palliative: to be repeated every 3 weeks until disease progression or intolerable toxicity.

Treatment Description:

Cycle	Date	TRASTuzumab	PERTuzumab	LVEF	Physician	Consultant
C# __						
C# __						
C# __						
C# __						
C# __						
C# __						

Important Notes:

Reported grade 3/4 toxicities: None Hematological Non-Hematological

If yes; Did it indicate hospitalization? Yes No

Did it indicate chemo-delay for ≥ 7 days? Yes No

Did it indicate dose reduction? Yes No

Did it indicate G-CSF support? Yes No